Function of NADPH Oxidases in Diabetic Nephropathy and Development of Nox Inhibitors

Abstract

Several recent studies have reported that reactive oxygen species (ROS), superoxide anion and hydrogen peroxide (H2O2), play important roles in various cellular signaling networks. NADPH oxidase (Nox) isozymes have been shown to mediate receptor-mediated ROS generation for physiological signaling processes involved in cell growth, differentiation, apoptosis, and fibrosis. Detectable intracellular levels of ROS can be induced by the electron leakage from mitochondrial respiratory chain as well as by activation of cytochrome p450, glucose oxidase and xanthine oxidase, leading to oxidative stress. The up-regulation and the hyper-activation of NADPH oxidases (Nox) also likely contribute to oxidative stress in pathophysiologic stages. Elevation of the renal ROS level through hyperglycemia-mediated Nox activation results in the oxidative stress which induces a damage to kidney tissues, causing to diabetic nephropathy (DN). Nox inhibitors are currently being developed as the therapeutics of DN. In this review, we summarize Nox-mediated ROS generation and development of Nox inhibitors for therapeutics of DN treatment.

Polysulfide-mediated sulfhydration of SIRT1 prevents diabetic nephropathy by suppressing phosphorylation and acetylation of p65 NF-κB and STAT3

“…Diabetic nephropathy is manifested by the presence of urine albumin excretion, glomerular lesions, mesangial expansion, renal and glomerular hypertrophy, and loss of glomerular filtration rate [ 87 , 88 ]. In this study, the therapeutic effects of Na 2 S 4 in diabetic nephropathy were evaluated in diabetic mice.…”

On the Clinical Pharmacology of Reactive Oxygen Species

“…This indication follows another phase II trial in type 1 diabetes and kidney disease launched in Australia (Table 2). APX-115 is also clinically developed for the same indication, i.e., diabetic nephropathy (Lee et al, 2020), moving from phase I to II, which was originally announced for 2019 but has not yet been listed in clinicaltrials.gov.…”

Photodynamic therapy regulates fate of cancer stem cells through reactive oxygen species

“…During PDT, BAP31 is cleaved before the mitochondria changes and mediates the release of ERS and Ca 2+[43] . From the point of view of enzyme catalysis, PDT regulates flavin adenine dinucleotide, ubiquinones, and cytochrome in mitochondrial respiratory chain complexes I and III to produce ROS[ 44 - 46 ]; mitochondrial triphosphopyridine nucleotide(NADPH) oxidase and xanthine oxidase catalyze the production of O 2− [ 47 ]; mitochondrial myeloperoxidase myeloperoxidase (MPO) catalyzes the production of OH; and protein kinase C catalyzes the production of H 2 O 2 [ 48 , 49 ]. Because the dynamic changes in ROS are rapid, in trace amounts, and complex, it is difficult to accurately detect the process by which ROS are produced, from exogenous to endogenous ROS, by PDT within a short period.…”